Influence of inhaled corticosteroids on pubertal growth and final height in asthmatic children

Leonibus, Chiara De; Attanasi, Marina; Roze, Zane; Martin, Benedetta; Marcovecchio, Maria Loredana; Pillo, Sabrina Di; Chiarelli, Francesco; Mohn, Angelika

doi:10.1111/pai.12558

Cited by 19 publications

(13 citation statements)

References 40 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Budesonide is the most widely used glucocorticoid for the treatment of asthmatic diseases [11]. The metabolic effects of budesonide are mediated through its binding to the glucocorticoid receptor, which is ubiquitously expressed in the human body.…”

mentioning

confidence: 99%

“…The glucocorticoid and beta2 agonist therapies are effective at controlling airway inflammation, reducing asthma symptoms, decreasing airway hyper-responsiveness and reducing the frequency and severity of exacerbations as well as asthma mortality. Despite their undoubted effectiveness and safety, there is still no consensus about the resulting metabolic derangements, including the development of dyslipidaemia, insulin resistance, glucose intolerance, diabetes, central adiposity and skeletal muscle wasting [5][6][7].Both glucocorticoids and beta2 agonists have the potential to influence glucose, lipid and protein metabolism [8][9][10].Budesonide is the most widely used glucocorticoid for the treatment of asthmatic diseases [11]. The metabolic effects of budesonide are mediated through its binding to the glucocorticoid receptor, which is ubiquitously expressed in the human body.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Distinct Metabolic Profile of Inhaled Budesonide and Salbutamol in Asthmatic Children during Acute Exacerbation

Yang

Zhang

et al. 2017

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Inhaled budesonide and salbutamol represent the most important and frequently used drugs in asthmatic children during acute exacerbation. However, there is still no consensus about their resulting metabolic derangements; thus, this study was conducted to determine the distinct metabolic profiles of these two drugs. A total of 69 children with asthma during acute exacerbation were included, and their serum and urine were investigated using high-resolution nuclear magnetic resonance (NMR). A metabolomics analysis was performed using a principal component analysis and orthogonal signal correction-partial least squares using SIMCA-P. The different metabolites were identified, and the distinct metabolic profiles were analysed using MetPA. A high-resolution NMR-based serum and urine metabolomics approach was established to study the overall metabolic changes after inhaled budesonide and salbutamol in asthmatic children during acute exacerbation. The perturbed metabolites included 22 different metabolites in the serum and 21 metabolites in the urine. Based on an integrated analysis, the changed metabolites included the following: increased 4-hydroxybutyrate, lactate, cis-aconitate, 5-hydroxyindoleacetate, taurine, trans-4-hydroxy-l-proline, tiglylglycine, 3-hydroxybutyrate, 3-methylhistidine, glucose, cis-aconitate, 2-deoxyinosine and 2-aminoadipate; and decreased alanine, glycerol, arginine, glycylproline, 2-hydroxy-3-methylvalerate, creatine, citrulline, glutamate, asparagine, 2-hydroxyvalerate, citrate, homoserine, histamine, sn-glycero-3-phosphocholine, sarcosine, ornithine, creatinine, glycine, isoleucine and trimethylamine N-oxide. The MetPA analysis revealed seven involved metabolic pathways: arginine and proline metabolism; taurine and hypotaurine metabolism; glycine, serine and threonine metabolism; glyoxylate and dicarboxylate metabolism; methane metabolism; citrate cycle; and pyruvate metabolism. The perturbed metabolic profiles suggest potential metabolic reprogramming associated with a combination treatment of inhaled budesonide and salbutamol in asthmatic children.Glucocorticoids and beta2 agonists represent the most important and frequently used drugs for symptom control in asthmatic children during acute exacerbation [1,2]. Current guidelines recommend the combined use of glucocorticoids and beta2 agonists as the preferred therapy for asthmatic children during acute exacerbation [3,4]. The glucocorticoid and beta2 agonist therapies are effective at controlling airway inflammation, reducing asthma symptoms, decreasing airway hyper-responsiveness and reducing the frequency and severity of exacerbations as well as asthma mortality. Despite their undoubted effectiveness and safety, there is still no consensus about the resulting metabolic derangements, including the development of dyslipidaemia, insulin resistance, glucose intolerance, diabetes, central adiposity and skeletal muscle wasting [5][6][7].Both glucocorticoids and beta2 agonists have the potential to influence glucose, lipid and protein...

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Distinct Metabolic Profile of Inhaled Budesonide and Salbutamol in Asthmatic Children during Acute Exacerbation

Yang

Zhang

et al. 2017

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…In this study, De Leonibus et al. analyzed growth patterns from prepuberty to the attainment of final height. The Authors investigated 113 asthmatic children with mild‐to‐moderate asthma under exclusive ICs treatment [budesonide (n = 36) vs. fluticasone (n = 43) vs. mometasone (n = 34)] compared to 66 healthy age‐matched controls.…”

Section: The Influence Of Inhaled Corticosteroids On Pubertal Growth mentioning

confidence: 99%

The Editor recommends this issue's articles to the reader

2016

Pediatric Allergy Immunology

View full text Add to dashboard Cite

“…Zum anderen bekommen viele Asthmatiker Glukokortikoide als Dauertherapie, die Einfluss auf die Größe der Kinder haben und die Fetteinlagerung fördern können (32). Auch die Zielgröße wird abhängig von Dauer, Dosis und Art der Glukokortikoide beeinflusst (33). Somit kann sich indirekt der BMI verändern.…”

Section: Abbunclassified

Stellt Übergewicht ein Risiko für die Entwicklung von Asthma bronchiale im Kindes- und Jugendalter dar?

Gramß¹,

Hiemisch²,

Kieß³

2016

Adipositas - Ursachen, Folgeerkrankungen, Therapie

View full text Add to dashboard Cite

ZusammenfassungIn den letzten beiden Jahrzehnten stiegen die Prävalenzen von Asthma bronchiale und Übergewicht parallel an. Für beide Erkrankungen werden ähnliche Ursachen diskutiert: umweltbezogene, genetische, sozioökonomische Faktoren und sogar die Einflussnahme durch Adipokine. Außerdem rückte das Übergewicht als potenzieller Auslöser und begünstigender Faktor von Asthma bronchiale in den Fokus der Forschung. Der BMI ist sowohl mit der Diagnose Asthma als auch mit dem Symptom „wheezing” positiv korreliert. Übergewichtige Kinder weisen größere IgESpiegel und häufiger Atopien auf. Jedoch zeigen Kinder mit größerem BMI häufiger nichtatopisches als atopisches Asthma bronchiale. Zudem sind allergische Tests wie bronchiale Hyperreagibilität und Skin Prick Tests bei adipösen Kindern nicht häufiger positiv als bei normalgewichtigen Kindern. Die Lungenfunktionswerte bei Übergewicht werden häufig als Minderung des Tiffeneau-Index (FEV1/FVK) beschrieben. Allerdings ist auch hier der Zusammenhang noch unklar, vor allem die Reaktion adipöser Kinder auf medikamentöse Broncholyse als Bestandteil der Spirometrie-Testung. Die nicht durchgängig einheitlichen und teilweise nicht signifikanten Studienergebnisse lassen daher nicht auf eine unmittelbare Verbindung von Asthma und Adipositas oder auf den Einfluss von Kovariablen auf deren Verhältnis schließen. Die LIFE Child-Kohorte soll zur Klärung offener Fragen beitragen.

show abstract

Influence of inhaled corticosteroids on pubertal growth and final height in asthmatic children

Abstract: ICs affect pubertal growth determining reduced final height in asthmatic children compared to controls, in a dose- and duration-dependent manner.

Cited by 19 publications

References 40 publications

Distinct Metabolic Profile of Inhaled Budesonide and Salbutamol in Asthmatic Children during Acute Exacerbation

Distinct Metabolic Profile of Inhaled Budesonide and Salbutamol in Asthmatic Children during Acute Exacerbation

The Editor recommends this issue's articles to the reader

Stellt Übergewicht ein Risiko für die Entwicklung von Asthma bronchiale im Kindes- und Jugendalter dar?

Contact Info

Product

Resources

About